Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
7.73
-0.29 (-3.62%)
At close: Aug 14, 2025, 4:00 PM
7.84
+0.11 (1.42%)
After-hours: Aug 14, 2025, 6:23 PM EDT
Verastem Revenue
Verastem had revenue of $2.14M in the quarter ending June 30, 2025, a decrease of -78.63%. This brings the company's revenue in the last twelve months to $2.14M, down -78.63% year-over-year. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$2.14M
Revenue Growth
-78.63%
P/S Ratio
189.49
Revenue / Employee
$27,397
Employees
78
Market Cap
475.74M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VSTM News
- 1 day ago - Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - Business Wire
- 5 days ago - Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 16 days ago - Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 21 days ago - Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - Business Wire
- 4 weeks ago - Verastem: The Market Is Ignoring The Progress - Seeking Alpha
- 4 weeks ago - Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Business Wire
- 5 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire